Reporting checklist for cohort study.

Based on the STROBE cohort guidelines.

Instructions to authors

Complete this checklist by entering the page numbers from your manuscript where readers will find each of the items listed below.

Your article may not currently address all the items on the checklist. Please modify your text to include the missing information. If you are certain that an item does not apply, please write "n/a" and provide a short explanation.

Upload your completed checklist as an extra file when you submit to a journal.

In your methods section, say that you used the STROBE cohortreporting guidelines, and cite them as:

von Elm E, Altman DG, Egger M, Pocock SJ, Gotzsche PC, Vandenbroucke JP. The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) Statement: guidelines for reporting observational studies.

		Reporting Item	Page Number
Title and abstract			
Title	#1a	Indicate the study's design with a commonly used term in the title or the abstract	Page: 3 Line: 50 Section: Abstract Paragraph: 1
Abstract	#1b	Provide in the abstract an informative and balanced summary of what was done and what was found	Page: 3-4 Line: 46-74 Section: Abstract Paragraph: 1-4
Introduction			

Background / rationale	#2	Explain the scientific background and rationale for the investigation being reported	Page: 5-8 Line: 92-164 Section: Introduction Paragraph: 1-4
Objectives	#3	State specific objectives, including any prespecified hypotheses	Page: 7-8 Line: 147-164 Section: Introduction Paragraph: 4
Methods			
Study design	#4	Present key elements of study design early in the paper	Page: 8 Line: 168-169 Section: Methods Paragraph: 1
Setting	#5	Describe the setting, locations, and relevant dates, including periods of recruitment, exposure, follow-up, and data collection	Page: 8 Line: 173-180 Section: Methods Paragraph: 2
Eligibility criteria	#6a	Give the eligibility criteria, and the sources and methods of selection of participants. Describe methods of follow-up.	Page: 8 Line: 178-180 Section: Methods Paragraph: 2
Eligibility criteria	#6b	For matched studies, give matching criteria and number of exposed and unexposed	N/A - This study was not a matched study.
Variables	#7	Clearly define all outcomes, exposures, predictors, potential confounders, and effect modifiers. Give diagnostic criteria, if applicable	Page: 8-15 Line: 181-310 Section: Methods, Results

			Paragraph: 3-11, 1
Data sources / measurement	#8	For each variable of interest give sources of data and details of methods of assessment (measurement). Describe comparability of assessment methods if there is more than one group. Give information separately for exposed and unexposed groups if applicable.	Page: 9-12 Line: 181-272 Section: Methods Paragraph: 3-9
Bias	#9	Describe any efforts to address potential sources of bias	Page: 13-14, 22-23 Line: 274-283, 486-498 Section: Methods, Limitations Paragraph: 10, 1
Study size	#10	Explain how the study size was arrived at	Page: 8 Line: 173-180 Section: Methods Paragraph: 2
Quantitative variables	#11	Explain how quantitative variables were handled in the analyses. If applicable, describe which groupings were chosen, and why	Page: 13-16 Line: 273-346 Section: Methods, Results Paragraph: 10-11, 1-3
Statistical methods	#12a	Describe all statistical methods, including those used to control for confounding	Page: 13-14 Line: 273-295 Section: Methods Paragraph: 10-11

Statistical methods	#12b	Describe any methods used to examine subgroups and interactions	N/A - There were no subgroups in this study.
Statistical methods	#12c	Explain how missing data were addressed	Page: 23 Line: 499-503 Section: Limitations Paragraph: 2
Statistical methods	#12d	If applicable, explain how loss to follow-up was addressed	Page: 13-14 Line: 273-283 Section: Methods Paragraph: 10
Statistical methods	#12e	Describe any sensitivity analyses	N/A – sensitivity analyses were conducted but not included in the manuscript.
Results			
Participants	#13a	Report numbers of individuals at each stage of study—eg numbers potentially eligible, examined for eligibility, confirmed eligible, included in the study, completing follow-up, and analysed. Give information separately for for exposed and unexposed groups if applicable.	Page: 15-16 Line: 315-336 Section: Results Paragraph: 1
Participants	#13b	Give reasons for non-participation at each stage	Page: 8

			Line: 173-180 Section: Methods Paragraph: 2
Participants	#13c	Consider use of a flow diagram	N/A - No flow chart was utilized for this
Descriptive data	#14a	Give characteristics of study participants (eg demographic, clinical, social) and information on exposures and potential confounders. Give information separately for exposed and unexposed groups if applicable.	Page: 15-16 Line: 315-336 Section: Results Paragraph: 2
Descriptive data	#14b	Indicate number of participants with missing data for each variable of interest	Page: 15-16 Line: 315-336 Section: Results Paragraph: 2
Descriptive data	#14c	Summarise follow-up time (eg, average and total amount)	Page: 15 Line: 315-316 Section: Results Paragraph: 2
Outcome data	#15	Report numbers of outcome events or summary measures over time. Give information separately for exposed and unexposed groups if applicable.	Page: 14-16 Line: 296-346 Section: Results Paragraph: 1-3

Main results	#16a	Give unadjusted estimates and, if applicable, confounder-adjusted estimates and their precision (eg, 95% confidence interval). Make clear which confounders were adjusted for and why they were included	Page: 14-16 Line: 296-346 Section: Results Paragraph: 1-3
Main results	#16b	Report category boundaries when continuous variables were categorized	Page: 14-16 Line: 296-346 Section: Results Paragraph: 1-3
Main results	#16c	If relevant, consider translating estimates of relative risk into absolute risk for a meaningful time period	N/A - risk was not assessed in this
Other analyses	#17	Report other analyses done—eg analyses of subgroups and interactions, and sensitivity analyses	Page: 14-16 Line: 296-346 Section: Results Paragraph: 1-3
Discussion			
Key results	#18	Summarise key results with reference to study objectives	Page: 17-23 Line: 352-484 Section: Discussion Paragraph: 1-8
Limitations	#19	Discuss limitations of the study, taking into account sources of potential bias or imprecision. Discuss both direction and magnitude of any potential bias.	Page: 23-24 Line: 486-524 Section: Limitations Paragraph: 1-3

Interpretation	#20	Give a cautious overall interpretation considering objectives, limitations, multiplicity of analyses, results from similar studies, and other relevant evidence.	Page: 17-23, 23-24, 24-25 Line: 352-484, 486-524, 526-535 Section: Discussion, Limitations, Conclusions Paragraph: 1-8, 1-3, 1
Generalisability	#21	Discuss the generalisability (external validity) of the study results	Page: 23 Line: 486-498 Section: Limitations Paragraph: 1
Other Information			
Funding	#22	Give the source of funding and the role of the funders for the present study and, if applicable, for the original study on which the present article is based	Page: 25 Line: 539 Section: Acknowledgements Paragraph: 1

Notes:

- 6b: N/A - This study was not a matched study.
- 12b: N/A - There were no subgroups in this study.
- 12e: N/A - sensitivity analyses were conducted but not included in the manuscript.
- 13c: N/A - No flow chart was utilized for this manuscript.
- 16c: N/A - risk was not assessed in this study.

Article information: https://dx.doi.org/10.21037/pm-21-53

*As the checklist was provided upon initial submission, the page number/line number reported may be changed due to copyediting and may not be referable in the published version. In this case, the section/paragraph may be used as an alternative reference.